On a beautiful Saturday in June, Children’s Hospital of Philadelphia (CHOP) hosted the first in-person Cure Sickle Cell Walk & Family Fun Day at Citizens Bank Park raising more than $173,000 to support CHOP’s large and comprehensive sickle cell program.

CHOP researchers have identified a molecule that plays a role in post-translational modification and activation in myeloid cancers, making it a potential therapeutic target.

CHOP gene therapy expert Dr. Lindsey George reacts to a phase 3 hemophilia gene therapy study in an editorial in the New England Journal of Medicine.

CHOP experts in bleeding disorders care and research presented at the American Society of Hematology 2022 conference.

Nearly 50 faculty, staff and trainees from the Division of Hematology and Division of Oncology at Children’s Hospital of Philadelphia attended the 64th Annual American Hematology Society (ASH) Meeting in New Orleans, Louisiana.

In a short documentary by the New England Journal of Medicine, Dr. Alexis Thompson discusses the early successes of gene therapy, as well as its risks and benefits.

A leading study site for nearly a decade, CHOP will be part of a network of treatment centers in the country offering the therapy to patients who require regular blood transfusions.

CHOP researchers have discovered a new part of the regulatory cascade responsible for silencing fetal hemoglobin in adult cells.

A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.

CHOP researchers have identified two transcription factors that are involved in silencing fetal hemoglobin in adult red blood cells.